Kintara up as FDA grants fast track designation to its breast cancer drug

TuHURA Biosciences

28/11/2022 14:00

** Kintara Therapeutics Inc's shares  KTRA.O  rise 33.4% to
$4.92 - stock among biggest pct. gainers across U.S. stock
exchanges premarket
    ** U.S. FDA granted fast track designation to KTRA's
experimental therapy to treat patients with a type of breast
cancer  urn:newsml:reuters.com:*:nPn6XwXZTa
    ** Fast Track designation is granted by the FDA to
facilitate development and expedite the review of therapies with
potential to treat a serious condition where there is an unmet
medical need
    ** Up to Friday's close, stock was down ~86% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))